CASSAVA SCIENCES INC Share · US14817C1071 · SAVA · A2PGL8 (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of CASSAVA SCIENCES INC

No Price

01.05.2026 21:26

Current Prices from CASSAVA SCIENCES INC

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	FLNA	USD	01.05.2026 21:26	1,50 USD	0,05 USD +3,45 %
IEX	FLNA	USD	01.05.2026 19:57	1,53 USD	0,07 USD +5,17 %
Düsseldorf	CSIRSD71.DUSB	EUR	30.04.2026 06:10	1,21 EUR	-
Hamburg	CSIRSD71.HAMB	EUR	30.04.2026 06:07	1,23 EUR	-
Quotrix	CSIRSD71.DUSD	EUR	30.04.2026 05:27	1,23 EUR	-

Share Float & Liquidity

Free Float 88,98 %

Shares Float 42,98 M

Shares Outstanding 48,31 M

Company Profile for CASSAVA SCIENCES INC Share

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.